Octapharma AG conducting Phase III trial to evaluate intravenous immunoglobulin (IVIG) in the treatment of Covid-19

The study is currently enrolling patients with Covid-19 who have been hospitalised due to complications from the disease. It follows positive results from a small randomised pilot study, in which it was associated with a reduction in hospital stay, among other benefits.

Source:

Biospace Inc.